Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ALMS1 intronic transcript 1 (ALMS1-IT1) is a long non-coding RNA that does not code for a protein and is derived from an intronic region of the ALMS1 gene. It has been identified as playing a regulatory role in several cancers, including colorectal cancer, colon adenocarcinoma, lung adenocarcinoma, and head and neck squamous cell carcinoma. Elevated expression of ALMS1-IT1 in cancer tissues has been associated with a worse prognosis. Functional studies suggest that ALMS1-IT1 can modulate ferroptosis (an iron-dependent form of cell death) and immune evasion, potentially through activation of pathways such as STAT3. Bioinformatic analyses indicate ALMS1-IT1 influences nucleosome and chromatin assembly, and is associated with epigenetic modifications such as DNA and histone methylation. It interacts with numerous microRNAs and RNA binding proteins and is significantly correlated with immune cell infiltration, particularly with NK cells and dendritic cells in tumor microenvironments. Due to its association with tumor progression and patient survival, ALMS1-IT1 is proposed as a novel prognostic biomarker in multiple malignancies[2][1][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ALMS1 intronic transcript 1 (ALMS1-IT1).